DAM
LCTX icon

DLD Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

DLD Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,000
Closed -$33.4K – 418
2025
Q4 		$33.4K Buy
+20,000
New +$34.6K ﹤0.01% 324

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DLD Asset Management's LCTX Position: Q1 2026 in Review

DLD Asset Management sold out of Lineage Cell Therapeutics (LCTX) in Q1 2026, closing a stake of 20,000 shares — an estimated $33.4K sold.

DLD Asset Management first reported a position in LCTX in Q4 2025 and held it in 1 quarter. The position peaked at $33.4K in Q4 2025. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • DLD Asset Management reported no remaining Lineage Cell Therapeutics position as of Q1 2026 after selling out during the quarter.
  • DLD Asset Management sold 20,000 Lineage Cell Therapeutics shares in Q1 2026, an estimated $33.4K.
  • DLD Asset Management first reported a position in Lineage Cell Therapeutics in Q4 2025 and held it in 1 quarter.
  • DLD Asset Management's Lineage Cell Therapeutics position peaked at $33.4K in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on DLD Asset Management's 13F filing for Q1 2026, filed 13 May 2026.